Clinical Trials Browser

Completed × Interventional × bemarituzumab × Clear all

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02318329 2024-06-04

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Phase 1 Completed

79 enrolled 21 charts

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

NCT03343301 2024-02-28

FIGHT

Phase 1 Completed

12 enrolled 17 charts

Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT03694522 2024-02-28

FIGHT

Phase 2 Completed

155 enrolled 19 charts

Gastrointestinal

Stomach Neoplasms

NCT05913115 2023-06-22

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Phase 1 Completed

6 enrolled

Gastrointestinal

Gastric or Gastroesophageal Cancer

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Phase 2 Completed

80 enrolled 14 charts

Tumor-Agnostic

Adenocarcinoma

Clinical Trials

FORTITUDE-301

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

FIGHT

FIGHT

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression